Investigational histone deacetylase inhibitors for treating pancreatic adenocarcinoma

Expert Opin Investig Drugs. 2016 Nov;25(11):1251-1254. doi: 10.1080/13543784.2016.1240167. Epub 2016 Oct 5.

Authors

Alexander Arlt¹, Heiner Schäfer²

Affiliations

¹ a Department of Internal Medicine I , Laboratory for Gastrointestinal Signal Transduction, UKSH Campus Kiel , Kiel , Germany.
² b Institute for Experimental Cancer Research , Laboratory of Molecular Gastroenterology, - Christian-Albrechts-University & UKSH Campus Kiel , Kiel , Germany.

PMID: 27666721
DOI: 10.1080/13543784.2016.1240167

No abstract available

Keywords: Drug resistance; epigenetic modulation; histone acetylation; pancreatic adenocarcinoma.

Publication types

Editorial

MeSH terms

Adenocarcinoma / drug therapy*
Adenocarcinoma / enzymology
Adenocarcinoma / pathology
Antineoplastic Agents / pharmacology
Antineoplastic Agents / therapeutic use
Drug Design
Drugs, Investigational / pharmacology
Drugs, Investigational / therapeutic use
Histone Deacetylase Inhibitors / pharmacology
Histone Deacetylase Inhibitors / therapeutic use*
Humans
Pancreatic Neoplasms / drug therapy*
Pancreatic Neoplasms / enzymology
Pancreatic Neoplasms / pathology

Substances

Antineoplastic Agents
Drugs, Investigational
Histone Deacetylase Inhibitors